Comparative Pharmacology
Head-to-head clinical analysis: GLUCAMIDE versus GLUCOTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCAMIDE versus GLUCOTROL.
GLUCAMIDE vs GLUCOTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucamide (glyburide) is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channel (K-ATP), leading to membrane depolarization, calcium influx, and exocytosis of insulin. It may also increase peripheral insulin sensitivity and reduce hepatic glucose production.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
50 mg orally twice daily, increased to 100 mg twice daily after 4 weeks if tolerated
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 12-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24-36 hours in severe renal impairment (CrCl <30 mL/min); clinical context: duration of hypoglycemic effect correlates with half-life in renal impairment.
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal excretion accounts for 5-10%.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic